263 related articles for article (PubMed ID: 7594225)
1. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
Ezzat S; Redelmeier DA; Gnehm M; Harris AG
J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
[TBL] [Abstract][Full Text] [Related]
2. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
Ho KY; Weissberger AJ; Marbach P; Lazarus L
Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
[TBL] [Abstract][Full Text] [Related]
4. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
5. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
6. Octreotide treatment of acromegaly. A randomized, multicenter study.
Ezzat S; Snyder PJ; Young WF; Boyajy LD; Newman C; Klibanski A; Molitch ME; Boyd AE; Sheeler L; Cook DM
Ann Intern Med; 1992 Nov; 117(9):711-8. PubMed ID: 1416572
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
[TBL] [Abstract][Full Text] [Related]
8. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
9. Effects of treatment with octreotide in acromegalic patients--a multicenter Italian study. Italian Multicenter Octreotide Study Group.
Arosio M; Macchelli S; Rossi CM; Casati G; Biella O; Faglia G
Eur J Endocrinol; 1995 Oct; 133(4):430-9. PubMed ID: 7581966
[TBL] [Abstract][Full Text] [Related]
10. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
12. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
Lorcy Y; Dejager S; Chanson P;
Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
[TBL] [Abstract][Full Text] [Related]
13. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
14. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
15. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
16. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
17. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly.
Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC
J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone and insulin-like growth factor-1 in blood and urine as response markers during treatment of acromegaly with octreotide: a double-blind placebo-controlled study.
Fredstorp L; Werner S
J Endocrinol Invest; 1993 Apr; 16(4):253-8. PubMed ID: 8514980
[TBL] [Abstract][Full Text] [Related]
19. Octreotide stimulates insulin-like growth factor binding protein-1 (IGFBP-1) levels in acromegaly.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1991 Aug; 73(2):441-3. PubMed ID: 1713220
[TBL] [Abstract][Full Text] [Related]
20. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
